Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - in Patients Undergoing Major Orthopaedic Surgery

Author： Mueck Wolfgang  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.47, Iss.3, 2008-01, pp. : 203-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

By  

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 75-83

Bentham Science Publishers

Access to resources Recommend Favorite

Rivaroxaban, the first oral, direct factor Xa inhibitor

By Fassiadis Nicholas  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 18, 2009-12 ,pp. : 2945-2946

Informa Healthcare

Access to resources Recommend Favorite

Rivaroxaban, an oral direct factor Xa inhibitor

By Piccini Jonathan P   Patel Manesh R   Mahaffey Kenneth W   Fox Keith AA   Califf Robert M  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 925-937

Informa Healthcare

Access to resources Recommend Favorite

Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty

By Borris Lars C  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 1083-1088

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite